New drugs, therapeutic strategies, and future direction for the treatment of pulmonary arterial hypertension

Valentina Mercurio; Anna Bianco; Giacomo Campi; Alessandra Cuomo; Nermin Diab; Angela Mancini; Paolo Parrella; Mario Petretta; Paul M. Hassoun; Domenico Bonaduce

doi:10.2174/0929867325666180201095743

New drugs, therapeutic strategies, and future direction for the treatment of pulmonary arterial hypertension

Valentina Mercurio, Anna Bianco, Giacomo Campi, Alessandra Cuomo, Nermin Diab, Angela Mancini, Paolo Parrella, Mario Petretta, Paul M. Hassoun, Domenico Bonaduce

School of Medicine

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.

Original language	English (US)
Pages (from-to)	2844-2864
Number of pages	21
Journal	Current medicinal chemistry
Volume	26
Issue number	16
DOIs	https://doi.org/10.2174/0929867325666180201095743
State	Published - 2019

Keywords

Gene therapy
Immunity
Inflammation
Initial combination therapy
Macitentan
Metabolism
Pulmonary arterial denervation
Pulmonary arterial hypertension
Riociguat
Selexipag
Serotonin

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Pharmacology
Drug Discovery
Organic Chemistry

Access to Document

10.2174/0929867325666180201095743

Cite this

@article{8bd83e3e01f340048bc856f940eedea2,

title = "New drugs, therapeutic strategies, and future direction for the treatment of pulmonary arterial hypertension",

abstract = "Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.",

keywords = "Gene therapy, Immunity, Inflammation, Initial combination therapy, Macitentan, Metabolism, Pulmonary arterial denervation, Pulmonary arterial hypertension, Riociguat, Selexipag, Serotonin",

author = "Valentina Mercurio and Anna Bianco and Giacomo Campi and Alessandra Cuomo and Nermin Diab and Angela Mancini and Paolo Parrella and Mario Petretta and Hassoun, {Paul M.} and Domenico Bonaduce",

note = "Publisher Copyright: {\textcopyright} 2019 Bentham Science Publishers.",

year = "2019",

doi = "10.2174/0929867325666180201095743",

language = "English (US)",

volume = "26",

pages = "2844--2864",

journal = "Current medicinal chemistry",

issn = "0929-8673",

publisher = "Bentham Science Publishers B.V.",

number = "16",

}

TY - JOUR

T1 - New drugs, therapeutic strategies, and future direction for the treatment of pulmonary arterial hypertension

AU - Mercurio, Valentina

AU - Bianco, Anna

AU - Campi, Giacomo

AU - Cuomo, Alessandra

AU - Diab, Nermin

AU - Mancini, Angela

AU - Parrella, Paolo

AU - Petretta, Mario

AU - Hassoun, Paul M.

AU - Bonaduce, Domenico

PY - 2019

Y1 - 2019

N2 - Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.

AB - Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.

KW - Gene therapy

KW - Immunity

KW - Inflammation

KW - Initial combination therapy

KW - Macitentan

KW - Metabolism

KW - Pulmonary arterial denervation

KW - Pulmonary arterial hypertension

KW - Riociguat

KW - Selexipag

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=85055125528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055125528&partnerID=8YFLogxK

U2 - 10.2174/0929867325666180201095743

DO - 10.2174/0929867325666180201095743

M3 - Review article

C2 - 29421995

AN - SCOPUS:85055125528

SN - 0929-8673

VL - 26

SP - 2844

EP - 2864

JO - Current medicinal chemistry

JF - Current medicinal chemistry

IS - 16

ER -

New drugs, therapeutic strategies, and future direction for the treatment of pulmonary arterial hypertension

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this